Helen Torley, PRESIDENT AND CEO at HALOZYME THERAPEUTICS, INC. (HALO), sold 119,792 shares at $57.62 ($6.8M) on 2025-07-10, disclosed to the SEC on 2025-07-10.
Scheduled sale ($6.8M) by PRESIDENT AND CEO under a pre-arranged 10b5-1 plan. Pre-set trade — not a discretionary signal on the stock.
Nothing distinguishes this filing.
| # | Price | Shares | Value | % of Total |
|---|---|---|---|---|
| 1 | $54.48 | 3,598 | $196K | 2.9% |
| 2 | $54.48 | 3,598 | $196K | 2.9% |
| 3 | $55.74 | 16,402 | $914K | 13.5% |
| 4 | $55.74 | 16,402 | $914K | 13.5% |
| 5 | $56.43 | 19,792 | $1.1M | 16.5% |
| 6 | $56.43 | 19,792 |
| $1.1M |
| 16.5% |
| 7 | $57.08 | 208 | $12K | 0.2% |
| 8 | $56.74 | 4,254 | $241K | 3.6% |
| 9 | $56.74 | 4,254 | $241K | 3.6% |
| 10 | $57.62 | 15,746 | $907K | 13.4% |
| 11 | $57.62 | 15,746 | $907K | 13.4% |
| Total | $56.46 avg | 119,792 | $6.8M | 100% |
| Filing → |
| HALO | SELL | 2026-08-19 | $6.3M | — | Filing → |
| HALO | SELL | 2026-07-09 | $153K | — | Filing → |
| HALO | SELL | 2026-06-03 | $3.4M | — | Filing → |